{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:26:45Z","timestamp":1760783205341},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context.<\/jats:title>\n                  <jats:p>Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from \u201cC\u201d cells of the thyroid; it is a RET associated cancer that can be sporadic or familial in origin. Advances in understanding the genetic changes associated with the development of MTC explain the growing interest in the therapeutic potential of tyrosine kinase inhibitors. Sunitinib is an orally administered multikinase inhibitor likely to target multiple pathways in the tumor, stromal, and endothelial compartments. Its role in the treatment of MTC patients has not yet been established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>To present the case of a patient with a sporadic and unresectable MTC who was successfully treated with sunitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patient and Results.<\/jats:title>\n                  <jats:p>A 55-year-old man with locally advanced MTC, without germinal and\/or somatic RET mutations, was started on sunitinib (50 mg\/day for 28 days, followed by 14 days of no treatment). At the time of writing, he had received four consecutive cycles. At the end of the first cycle, his serum calcitonin level had dropped by 81%. In the following cycles, a long-lasting minor response was observed. An early and dramatic tumor reduction, particularly of a cervical lymph node conglomerate, was observed and confirmed by the Response Evaluation Criteria in Solid Tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Sunitinib may play a role in the management of patients with locally advanced MTC or distant metastatic disease, for which no effective systemic therapy exists. Moreover, the absence of RET mutations does not seem to be an exclusion criterion for sunitinib treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2009-0195","type":"journal-article","created":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T04:26:00Z","timestamp":1257308760000},"page":"1083-1087","source":"Crossref","is-referenced-by-count":11,"title":["A Case of Advanced Medullary Thyroid Carcinoma Successfully Treated with Sunitinib"],"prefix":"10.1093","volume":"14","author":[{"given":"Maria Jo\u00e3o","family":"Bugalho","sequence":"first","affiliation":[{"name":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal"},{"name":"Centro de Investiga\u00e7\u00e3o de Patobiologia Molecular, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal"},{"name":"Servi\u00e7o de Radiologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal"},{"name":"Cl\u00ednica Universit\u00e1ria de Endocrinologia, Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"Rita","family":"Domingues","sequence":"additional","affiliation":[{"name":"Centro de Investiga\u00e7\u00e3o de Patobiologia Molecular, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal"}]},{"given":"Alexandra","family":"Borges","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Radiologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil E.P.E., Lisboa, Portugal"}]}],"member":"286","published-online":{"date-parts":[[2009,11,3]]},"reference":[{"key":"2021122207131929300_R1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"key":"2021122207131929300_R2","first-page":"3740","article-title":"Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma","volume":"81","author":"Wohllk","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122207131929300_R3","first-page":"1619","article-title":"Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence","volume":"81","author":"Romei","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122207131929300_R4","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br J Cancer"},{"key":"2021122207131929300_R5","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: From rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122207131929300_R6","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122207131929300_R7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":"SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model","volume":"20","author":"Murray","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"2021122207131929300_R8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122207131929300_R9","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1517\/14656566.8.14.2359","article-title":"Sunitinib","volume":"8","author":"Rini","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"2021122207131929300_R10","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207131929300_R11","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1210\/jc.2005-2845","article-title":"An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET\/papillary thyroid cancer kinases","volume":"91","author":"Kim","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122207131929300_R12","doi-asserted-by":"crossref","first-page":"567","DOI":"10.7326\/0003-4819-148-7-200804010-00027","article-title":"Response to sunitinib in medullary thyroid cancer","volume":"148","author":"Kelleher","year":"2008","journal-title":"Ann Intern Med"},{"key":"2021122207131929300_R13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0b013e3282fc6cf7","article-title":"Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma","volume":"19","author":"Dawson","year":"2008","journal-title":"Anticancer Drugs"},{"issue":"15 suppl","key":"2021122207131929300_R14","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1200\/jco.2008.26.15_suppl.6025","article-title":"Phase 2 study of sunitinib in refractory thyroid cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122207131929300_R15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1210\/er.2006-0017","article-title":"RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors","volume":"27","author":"Groot","year":"2006","journal-title":"Endocr Rev"},{"key":"2021122207131929300_R16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1210\/jc.2008-0923","article-title":"Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers","volume":"94","author":"Sherman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122207131929300_R17","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122207131929300_R18","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"2021122207131929300_R19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1358\/dot.2006.42.10.1025318","article-title":"Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy","volume":"42","author":"Sathornsumetee","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"2021122207131929300_R20","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/0008-5472.CAN-06-4605","article-title":"The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells","volume":"67","author":"Akeno-Stuart","year":"2007","journal-title":"Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2009-0195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2009-0195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/11\/1083\/41841768\/oncolo_14_11_1083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/14\/11\/1083\/41841768\/oncolo_14_11_1083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T07:28:37Z","timestamp":1640158117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/14\/11\/1083\/6398785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":20,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,11,3]]},"published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2009-0195","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,11,1]]},"published":{"date-parts":[[2009,11,1]]}}}